PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Colchicine

Drugs in development · updated 30 October 2026

Colchicine: clinical trials and development status

Other names and codes: Lodoco, Gloperba, Mitigare, Colcrys

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 24 July 2026

As of 30 October 2026 Colchicine is in 52 active clinical trials (recruiting or ongoing, phases I–III) for 64 diseases. The most advanced phase is III.

52Active trials
IIIMost advanced phase
64Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Colchicine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 64 diseases.

DiseaseMost advanced phaseActive trialsReference trial
InflammationIII12NCT04774159
Cardiovascular diseaseIII8NCT05633810
AtherosclerosisIII6NCT06930885
StrokeIII6NCT04774159
Heart diseaseIII5NCT05633810
Cerebral hemorrhageIII4NCT06587737
Atrial fibrillationIII3NCT07887022
Chronic renal insufficiencyIII3NCT06998862
Coronary artery diseaseIII3NCT06095765
Heart failureIII3NCT05873881
Myocardial infarctionIII3NCT04774159
Ischemic strokeIII2NCT06352632
MyocarditisIII2NCT06158698
Peripheral Arterial DiseaseIII2NCT04774159
Postthrombotic SyndromeIII2NCT06440694
Type 2 diabetesIII2NCT05633810
Venous thromboembolismIII2NCT06440694
Aortic valve calcificationIII1NCT05162742
Aortic valve diseaseIII1NCT05162742
Aortic valve stenosisIII1NCT05162742
Arrhythmias, CardiacIII1NCT05890664
Autoimmune thyroiditisII–III1NCT07571681
CalcinosisIII1NCT05162742
CardiomyopathiesIII1NCT06158698
Cerebral infarctionIII1NCT05476991
Chronic Limb-Threatening IschemiaIII1NCT07536373
Community-acquired pneumoniaIII1NCT04381936
Coronary DiseaseIII1NCT06472908
COVID-19III1NCT04381936
Hashimoto DiseaseII–III1NCT07571681

Everything on Colchicine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch